Drugs / SPX-101
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05231733 | May 2022 → Apr 2024 | cancer | SparX Biotech(Jiangsu) Co., Ltd. | Withdrawn | No outcome recorded Stop: Business |
| Phase 1 | NCT03056989 | May → Aug 2017 | cystic fibrosis | Spyryx Biosciences, Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03229252 | Aug 2017 → Jun 2019 | cystic fibrosis | Spyryx Biosciences, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SPX-101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03229252 ↗ |
| Modality | Protein / enzyme biologic | — CHEMBL6068525 ↗ |
| Route | Inhaled | “nebulized SPX-101” PMID 31302339 ↗ Jul 2019 |